We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Innova and TGR Enter Co-Marketing Agreement for Complementary Core Biotechnologies

By LabMedica International staff writers
Posted on 02 Feb 2014
Combining ELISA technology from TGR BioSciences (Adelaide, Australia) with conjugation kits from Innova Biosciences (Cambridge, UK) improves ELISA sensitivity and reduces cost.

TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.

TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.

TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.

“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”

Related Links:

TGR BioSciences
Innova Biosciences


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
New
Gold Member
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more